Clinical trials: Aripiprazole, completed
Irritable Mood, ADHD
Irritability in Children With ADHD and Emotion Dysregulation
Objective: Emotion dysregulation is common among children with ADHD and associated with a broad range of adult psychopathology, which is similar to the longitudinal outcomes of childhood irritability.
- Trial name
- NCT05974241
- Testing
- Methylphenidate, aripiprazole, and combination
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Immunoassay, Antipsychotic
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
The purpose of this study is to collect whole blood and plasma venous and capillary samples from participants taking aripiprazole, olanzapine, paliperidone, or risperidone for the development of antipsychotic immunoassays.
- Trial name
- NCT02634463
- Testing
- Aripiprazole, Olanzapine, Paliperidone
- Where
- Belgium
- Volunteers
- 81 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a…
- Trial name
- ATTAIN 266 (NCT01149655)
- Testing
- Aripiprazole
- Where
- 52 sites in United States, India and 5 more
- Volunteers
- 252 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.
- Trial name
- NCT00392197
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 111 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC
Bipolar Disorders, Metabolic Complication
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders
The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.
- Trial name
- NCT00845988
- Testing
- aripiprazole
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters.
- Trial name
- NCT05542264
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
HIV Infections
Bioequivalence Study of Atazanavir 300 mg Capsule
The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.
- Trial name
- NCT00393328
- Testing
- Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
This is a phase 3, multicenter, randomized, active-controlled trial to assess the efficacy and safety of aripiprazole Intramuscular Depot in the acute treatment of adults with schizophrenia.
- Trial name
- NCT03172871
- Testing
- Aripiprazole IM Depot, Aripiprazole tablet
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Otsuka Beijing Research Institute
Tourette's Disorder, Tic Disorder
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine efficacy and safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727700
- Testing
- Aripiprazole
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 133 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autistic Disorder
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
- Trial name
- BAART (NCT01333072)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY…
- Trial name
- NCT03919994
- Where
- 57 sites in United States
- Volunteers
- 338 people
- Sponsor
- Alkermes, Inc.
Generalized Anxiety Disorder, Panic Disorder
Aripiprazole for the Treatment of Refractory Anxiety
The purpose of this study is to determine whether aripiprazole is effective in the treatment of refractory panic and generalized anxiety disorder.
- Trial name
- NCT00438386
- Testing
- Aripiprazole
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data…
- Trial name
- DOMINO (NCT03005769)
- Where
- 20 sites in Italy
- Volunteers
- 262 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd